The Relationship Of EPO Over-Expression To VHL Mutations And Hif1α And 2α In SCCRCC
The authors evaluated expression of erythropoietin (EPO), a target gene of HIF, and correlated this to expression of HIF-1alpha and HIF-2alpha in 82 patients with sporadic RCC. EPO expression was found in 65% of tumors that expressed HIF-1alpha and in 84.1% of tumors that were HIF-2alpha positive.
Targeted disruption of the HIF pathway has proven successful in medical treatment of advanced RCC, and further delineation of the HIF pathway through investigations such as this are necessary to catalyze intelligent drug design.
Presented by Kan Gong, MD, Kai Zhang, MD, Ning Zhang, MD, and Qun Yan Na, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.
Reported by UroToday.com Contributing Editor Alexander Kutikov, MD
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2008 - UroToday
Relaþia dintre EPO Peste-Exprimarea Pentru a VHL mutaþii ªi Hif1? ªi 2? În SCCRCC - The Relationship Of EPO Over-Expression To VHL Mutations And Hif1α And 2α In SCCRCC - articole medicale engleza - startsanatate